For the first time since the beginning of the pandemic, 15,150 new cases of COVID-19 have been detected in Russia - almost 1,400 more than the day before. 232 deaths were recorded.
5,049 new cases of COVID-19 have been confirmed in Moscow. For the first time in the fall, this figure exceeded 5 thousand, and this is the maximum since May 12. The number of new cases of coronavirus in the past week is almost 29.5% more than in the previous week.
Business FM commentator Andrey Romashkov comments on the new data.
“Records have been updated for almost every indicator: for the first time, more than 15 thousand diagnoses in Russia; for the first time more than 10 thousand per day outside the capital; for the first time since mid-May, more than 5 thousand in Moscow. The number of active cases of coronavirus in the country exceeded 280 thousand - in the spring there was a maximum of 240. Today 232 patients have died, over the past seven days almost 1.5 thousand. At the peak of the spring outbreak, just over 1,000 patients died in a week.
Since the beginning of the month, both federal and metropolitan authorities have been repeating one thing: if the existing restrictions are observed, new ones will not be required. Judging by the measures introduced, this did not happen. During this week, the city authorities managed to fine countless retail outlets and bars, send high school students to a two-week remote location, start collecting data on remote employees of companies and oblige Muscovites to go to nightclubs using a QR code or SMS.
When the incidence chart hits a plateau, one can only guess. Alexander Gorelov, deputy director of the Central Research Institute of Epidemiology of Rospotrebnadzor, told Interfax that the situation could stabilize in November - after the end of two incubation periods of infection. According to the expert, the peak values of the autumn outbreak of the virus can range from 17 thousand to 18 thousand cases per day."
In Moscow, 1,140 patients with COVID-19 were hospitalized per day. There are 318 people on mechanical ventilation in the capital's hospitals.
Sergei Sobyanin said that Moscow in the coming weeks will definitely withstand the situation with the spread of coronavirus, the main thing is that the numbers stabilize. In an interview with TASS, the mayor of the capital said that four reserve hospitals have been created in the city, two of them are already being filled, but he hopes that they will not be needed in full.
Sobyanin also said that by the end of October - November, Moscow will receive the first large batches of the vaccine. As for the opponents of the Russian vaccination against the coronavirus, the mayor believes that this is "the order of competitors."
“There has been a whole campaign around coronavirus vaccinations about how scary, terrible and problematic it is. I think that most of this company is just a contract from competitors who do not want to be beaten by their competitors and want to make their own vaccine at that time and put it on the market. At least this is the attitude towards the Russian vaccine; we see a whole systemic campaign aimed at discrediting this vaccine. I hope that at the end of October - early November there will be the first batches, more or less large batches of the vaccine. At the end of the year, we will already receive the consignments that are necessary for mass vaccination."
WHO, meanwhile, has recognized several drugs used to treat coronavirus as ineffective. We are talking about "Remdesivir", hydroxychloroquine, lopinavir and interferon. None of these drugs improved a patient's chances of survival, according to new research from the World Health Organization. Earlier, the WHO, in particular, stated that "Remdesivir" is giving "encouraging" results. What has changed since then? Vyacheslav Ovechkin, a pulmonologist at the Semashko Clinical Hospital of Russian Railways Medicine, comments.
Vyacheslav Ovechkin, pulmonologist at the Semashko Clinical Hospital "Russian Railways Medicine" "Lopinavir is no longer included in the latest recommendations of the Ministry of Health for the treatment of coronavirus infection. Hydroxychloroquine is still in domestic recommendations, but only with a mild course of the disease. There is still no final data on it either, clinical trials have been carried out in Russia, they have not been fully published, but its significance has been reduced. Remdesivir was pre-approved even by the FD in America, when the first data appeared on a limited group of patients with COVID-19 directly in the United States, and it was included, then it was included in the US experience by other studies. At that time, there was a fairly small sample, a small number of people were treated. Now, apparently, complete data have already been obtained, a more detailed analysis has been carried out on a fairly large sample of patients, and this, in principle, is logical. If at the initial stage we saw efficiency on a limited sample, when we turn to large numbers, we turn to real statistics, it may turn out that the data do not correspond, this is precisely due to the limitedness of the initial sample."
The manufacturer of the drug, the American company Gilead Sciences, previously said that the use of Remdesivir shortens the recovery period to four days. In July, Donald Trump announced that the United States had bought 90% of the world's stock of the drug. The president himself was recently treated with him. The United States, Japan, South Korea, India, Israel, the United Kingdom and Russia have also approved the use of Remdesivir for the treatment of COVID-19.
In October, several European countries ordered 500 thousand courses of Remdesivir from the manufacturer for the treatment of COVID-19, RBC notes. The cost of one course exceeds $ 2,000.
On October 16, the FAS agreed to the first two pharmaceutical manufacturers on the maximum selling price for drugs based on the active ingredient favipiravir - 100 rubles per tablet. Thus, a pack of 50 tablets will cost 5500 rubles excluding regional surcharges. The cost of the drug after the registration of the price will decrease by at least half, the FAS assured.